Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBC-664 in Advanced Solid Tumors
NCT07705035Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of DBC-664 in solid tumor, malignant germ cell tumor (MGCT), lung adenocarcinoma and 6 more (2 arms). Primary endpoints: Safety and Tolerability at 2 years, Recommended Dose for Expansion at 1 year and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
DBC-664
03
Conditions
solid tumormalignant germ cell tumor (MGCT)lung adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07705035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705035.